Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
working full-time. The Health Data Research (HDR) UK Medicines in Acute and Chronic Care Driver Programme is a UK-wide multidisciplinary collaboration of clinical, data and discovery scientists focussed
-
expected to contribute to recruitment efforts and perform administrative roles for the subject. This is an exciting opportunity to contribute to a lively and inclusive academic community that values
-
preGnancy hEalth aNd elevaTed heAt) at Swansea University. Funded by the Wellcome Trust, MAGENTA explores how heat exposure and climate change affect pregnancies health across our communities. This is a
-
About The University Swansea University is a research-led university that has been making a difference since 1920. The University community thrives on exploration and discovery and offers the right balance of excellent teaching and research, matched by an enviable quality of life. Our stunning...
-
Performance, Planning and Insights team, ensuring best practice is shared and supporting the alignment of priorities. This role is integral to the Marketing Intelligence team’s ability to provide evidence-based
-
of the techniques we use (for instance cryogenics, ultra-high vacuum and Labview) will be appreciated, though are not formal requirements. In addition to salary, there is an overseas allowance
-
paramedic science as well as other subject areas (preferably utilising innovative teaching methods such as high-fidelity simulation). The successful candidate will be given support to further their academic
-
on Experimental Study and Computational Solids Mechanics model of soft multifunctional materials such as magneto-active polymers (MAPs), Electro-active polymers (EAPs). The successful candidate will work on the
-
Longitudinal Cohort Evaluation (LCE) of participants in a campus-based STEM outreach programme . The LCE has been delivered and the drafts of reports and papers completed. The Research Officer will complete full
-
, significantly increasing lifetime CRC risk up to 90%, with a 63% cumulative risk by age 60. MAP patients are additionally at high-risk for duodenal cancer and other extra-colonic manifestations. The clinical